OPKO Health’s (OPK) “Outperform” Rating Reaffirmed at Barrington Research

OPKO Health (NASDAQ:OPK)‘s stock had its “outperform” rating reiterated by analysts at Barrington Research in a research note issued on Thursday,Benzinga reports. They currently have a $2.25 price objective on the biotechnology company’s stock. Barrington Research’s price target suggests a potential upside of 62.45% from the company’s previous close.

A number of other equities research analysts have also recently issued reports on the stock. JPMorgan Chase & Co. began coverage on shares of OPKO Health in a report on Friday, April 25th. They set a “neutral” rating on the stock. HC Wainwright reiterated a “buy” rating and set a $3.00 price objective on shares of OPKO Health in a research note on Monday, April 7th. Finally, StockNews.com upgraded OPKO Health from a “sell” rating to a “hold” rating in a research note on Monday, March 3rd. Two equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. According to MarketBeat.com, OPKO Health presently has an average rating of “Moderate Buy” and a consensus target price of $2.75.

OPKO Health Stock Performance

NASDAQ:OPK opened at $1.39 on Thursday. The company has a market capitalization of $930.10 million, a P/E ratio of -7.29 and a beta of 1.42. The business has a fifty day simple moving average of $1.61 and a two-hundred day simple moving average of $1.57. The company has a debt-to-equity ratio of 0.30, a current ratio of 2.97 and a quick ratio of 2.69. OPKO Health has a 1 year low of $1.15 and a 1 year high of $2.04.

OPKO Health (NASDAQ:OPK) last announced its quarterly earnings data on Wednesday, April 30th. The biotechnology company reported ($0.10) earnings per share for the quarter, missing the consensus estimate of ($0.07) by ($0.03). The firm had revenue of $149.90 million during the quarter, compared to analysts’ expectations of $163.13 million. OPKO Health had a negative return on equity of 9.76% and a negative net margin of 18.65%. The company’s revenue was down 13.7% compared to the same quarter last year. During the same period last year, the business posted ($0.12) EPS. On average, analysts expect that OPKO Health will post -0.25 earnings per share for the current year.

Insider Buying and Selling

In other OPKO Health news, CEO Phillip Md Et Al Frost bought 125,000 shares of the firm’s stock in a transaction that occurred on Thursday, April 10th. The shares were bought at an average price of $1.36 per share, for a total transaction of $170,000.00. Following the transaction, the chief executive officer now directly owns 214,001,448 shares in the company, valued at $291,041,969.28. This trade represents a 0.06 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Over the last ninety days, insiders purchased 767,434 shares of company stock worth $1,238,312. Corporate insiders own 49.69% of the company’s stock.

Institutional Trading of OPKO Health

Institutional investors have recently added to or reduced their stakes in the business. Cerity Partners LLC bought a new stake in shares of OPKO Health in the 1st quarter valued at about $36,000. Wealth Enhancement Advisory Services LLC lifted its position in OPKO Health by 75.3% in the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 28,908 shares of the biotechnology company’s stock valued at $42,000 after purchasing an additional 12,417 shares during the last quarter. Pallas Capital Advisors LLC bought a new stake in OPKO Health in the first quarter valued at approximately $43,000. Cibc World Markets Corp purchased a new stake in shares of OPKO Health during the fourth quarter valued at approximately $45,000. Finally, Zacks Investment Management purchased a new position in shares of OPKO Health in the fourth quarter worth $49,000. 64.63% of the stock is currently owned by hedge funds and other institutional investors.

About OPKO Health

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.